Clinical Trials Logo

Schizophrenia clinical trials

View clinical trials related to Schizophrenia.

Filter by:

NCT ID: NCT00211380 Terminated - Schizophrenia Clinical Trials

Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI)

Start date: August 2003
Phase: N/A
Study type: Interventional

This is the sister study to the BMS "Cognitive Improvement with Aripiprazole (Abilify)" study (LSUHSC #H04-022). Evaluation of cognitive ability in patients with schizophrenia or schizoaffective disorder both before and after a switch from risperidone, olanzapine, or risperidone Consta injections to aripiprazole may reveal some of the cognitive changes that correlate with the improved response, better side effect profile, and effects on other components of the negative symptom array. Further, examination of brain functional activity using functional magnetic resonance imaging (fMRI) during an episodic memory task, as well as behavioral performance and associated electroencephalographic (EEG) data of working memory and intermediate term verbal memory collected with the Sustained Attention and Memory Brain Function Test (SAM-BFT), may also provide data showing the neural correlates of these changes in cognition.

NCT ID: NCT00211302 Terminated - Schizophrenia Clinical Trials

Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)

Start date: August 2003
Phase: N/A
Study type: Interventional

Evaluation of cognitive ability in patients with schizophrenia or schizoaffective disorder both before and after a switch from risperidone to aripiprazole may reveal some of the cognitive changes that correlate with the improved response, better side effect profile, and effects on other components of the negative symptom array. Further, examination of brain functional activity using functional magnetic resonance imaging (fMRI) during a verbal learning task, as well as behavioral performance and associated electroencephalographic (EEG) data of episodic memory, working memory and intermediate term verbal memory collected with the Sustained Attention and Memory Brain Function Test (SAM-BFT), may also provide data showing the neural correlates of these changes in cognition.

NCT ID: NCT00209027 Terminated - Schizophrenia Clinical Trials

The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia

Start date: April 2005
Phase: N/A
Study type: Interventional

The objective of this study is to determine whether subjects with negative symptoms of schizophrenia have abnormal functioning of brain circuits relevant to reward processing, and to determine whether any such abnormalities are normalized by treatment with aripiprazole.

NCT ID: NCT00206947 Terminated - Schizophrenia Clinical Trials

The CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in Schizophrenia

Start date: December 2002
Phase: Phase 2
Study type: Interventional

The present study will specify and delineate the separate components of cognitive deficits and examine the effects of adjunctive cholinergic augmentation on these cognitive deficits as well as psychopathology in schizophrenic patients treated with an antipsychotic compound with no aberrant binding affinity for the cholinergic receptor system. The hypothesis is that cholinergic augmentation using donepezil will improve cognitive deficits, sensory gating deficits, and psychopathology in schizophrenic patients treated with an atypical antipsychotic (ziprasidone).

NCT ID: NCT00184509 Terminated - Schizophrenia Clinical Trials

Continued Early Intervention for Recent-onset Schizophrenia

Start date: February 1993
Phase: Phase 3
Study type: Interventional

The purpose of this study was to determine whether outreach integrated treatment of first episode schizophrenia was more effecive than standard outpatient treatment.

NCT ID: NCT00169091 Terminated - Schizophrenia Clinical Trials

Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia

Start date: March 1996
Phase: Phase 4
Study type: Interventional

This study will examine the physical responses brought on by clozapine and haloperidol in people experiencing their first episode of schizophrenia.

NCT ID: NCT00169039 Terminated - Schizophrenia Clinical Trials

Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia

Start date: December 1994
Phase: Phase 4
Study type: Interventional

This study will examine the physical response to clozapine or chlorpromazine in people with schizophrenia that has not improved with treatment.

NCT ID: NCT00169026 Terminated - Schizophrenia Clinical Trials

Alcoholism and Schizophrenia: Effects of Clozapine

Start date: May 1999
Phase: Phase 4
Study type: Interventional

The purpose of this study is to examine the short - term effects of clozapine on alcohol use in persons with schizophrenia and an alcohol use disorder. The hypothesis is that clozapine will have greater efficacy in reducing alcohol use than other antipsychotic medications.

NCT ID: NCT00159757 Terminated - Schizophrenia Clinical Trials

12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients

Start date: November 2003
Phase: Phase 4
Study type: Interventional

There has been evidence that ziprasidone is efficacious in decreasing the magnitude of both positive and negative symptoms of schizophrenia, and also effective in the treatment of depressive symptoms. It shows good tolerance with low incidence of extrapyramidal side effects and does not significantly influence body weight. As it has been shown that ziprasidone is efficacious and safe in patients who have been pretreated with other antipsychotic that has to be withdrawn either due to the side effects or not satisfied efficacy. The purpose of the study was to provide further evidence for the efficacy and safety of patients with schizophrenia and allow for psychiatrists in Hungary to gain experience with the drug before wide commercial availability.

NCT ID: NCT00155636 Terminated - Schizophrenia Clinical Trials

A Study on Etiological Factors of Schizophrenia

Start date: January 2002
Phase: N/A
Study type: Observational

This PPG entitled “A Study on Etiological Factors of Schizophrenia” (SEFOS) focuses on searching for the separate etiological factors under the understanding that schizophrenia is a complex disorder. Multifactorial model has been most often proposed as the etiological model. Up to now, fragmented knowledge of etiological factors, including genetic factor and environmental insults were reported in literature, and a two-strike hypothesis has been proposed. This PPG of SEFOS formulates a dynamic etiological hypothesis of schizophrenia. Specific, however heterogeneous, genes are hypothesized to be located in chromosome 1q, 6P, 8P, 15q, and 22q; specific environmental insults or stress are hypothesized to be acting in the vulnerable brain a long different stages of biological and/or psychological development. The interaction of specific genes and specific environment insults/stress along different stages of development will result in specific neurobiological abnormalities as shown in neuropsychological, neurophysiological and neurochemical/neuroimaging abnormalities. For this hypothesis testing, this PPG of SEFOS designs 3 projects of: (1) A Study on Neurobiology of Schizophrenia; (2) A Study on Environmental insults/stress of schizophrenia; and (3) Molecular Genetics Study of Schizophrenia. Project No.1 aims at finding different levels of neurobiological and anatomical abnormalities; Project No.2 aims at finding different levels of environmental insults/ stress; Project No.3 aims at locating vulnerability genes in different chromosome regions. A core unit for administrative integration, for case/family recruitment and statistical analysis is also designed. The dynamic etiological complex will be explored under multivariate statistical analysis. This PPG of SEFOS adopts multidisciplinary approach including clinical psychiatrists, psychopathologists, neuropsychologist, neurophysiologist, neuroimaging (magnetic resonance imaging) specialist, genetic epidemiologist, molecular genetic specialist, genetic statistician, and biostatisticians. This team has sound mutual trust base on the experience of being working together and attending regular research meeting for the part several years under the leadership of the principal investigator of this PPG.